Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective

References

• Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. Journal of Clinical Oncology 2003; 21: 366–373
   PubMed Web of Science ®Google Scholar
• Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68((Suppl 1))3–11
   Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute 1999; 91: 1616–1634
   PubMed Web of Science ®Google Scholar
• Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Seminars in Hematology 1997; 34: 20–26
   PubMed Web of Science ®Google Scholar
• Berndt E, Kallich J, McDermott A, et al. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. PharmacoEconomics 2005; 23: 505–514
   PubMed Web of Science ®Google Scholar
• Tchekmedyian NS, Kallich J, McDermott A, et al. The relationship between psychologic distress and cancer-related fatigue. Cancer 2003; 98: 198–203
   PubMed Web of Science ®Google Scholar
• Littlewood T, Zambrowski JJ, Cornes P. Treating anaemia: deconstructing healthcare costs. Current Medical Research and Opinion 2006; 22((Suppl 4))S23–S33
   Google Scholar
• Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. Journal of Managed Care Pharmacy 2005; 11: 565–574
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™, Version 2. Fort Washington, PA: NCCN, 2006. Available at: http://www.nccn.org/professionals/physician_gls/default.asp [accessed April 2006]
   Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 2001; 84((Suppl 1))3–10
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nature Biotechnology 2003; 21: 414–421.
   PubMed Web of Science ®Google Scholar
• Powell J, Gurk-Turner C. Darbepoetin alfa (Aranesp). Proceedings (Baylor University Medical Center) 2002; 15: 332–335
   PubMedGoogle Scholar
• Rearden T, Charu V, Saidman B, et al. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). Journal of Clinical Oncology 2004; 22((Suppl))745S
   Google Scholar
• Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer 2003; 39: 2026–2034
   PubMed Web of Science ®Google Scholar
• Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology 2006; 24: 2290–2297
   PubMed Web of Science ®Google Scholar
• Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. American Journal of Health-System Pharmacy 2005; 62: 54–62
   PubMed Web of Science ®Google Scholar
• Glaspy J, Applebaum S, Henry D, et al. Darbepoetin alfa 6.75 mcg/kg every 3 weeks (Q3W) may be synchronized with Q3W chemotherapy to alleviate anemia in cancer patients. Annals of Oncology 2004; 15((Suppl))iii219–iii220
   Google Scholar
• Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. European Journal of Cancer 2005; 41: 1140–1149
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Aranesp® (darbepoetin alfa) prescribing information. Thousand Oaks, CA: Amgen Inc., 2006.
   Google Scholar
• Ortho Biotech Products L.P. Procrit® (epoetin alfa) prescribing information. Bridgwater, NJ: Ortho Biotech Products L.P., 2006.
   Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. Journal of the National Cancer Institute 2006; 98: 273–284
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Einhorn LH, Livingston RB, et al. Once-weekly dosing of epoetin alfa is similar to three-times weekly dosing in increasing hemoglobin and quality of life. Proceedings of the American Society of Clinical Oncology 1999; 18: 574a
   Google Scholar
• Cremieux PY, Fastenau JM, Kosicki G, et al. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. Journal of Managed Care Pharmacy 2004; 10: 531–537
   PubMedGoogle Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology 2001; 19: 2875–2882.
   PubMed Web of Science ®Google Scholar
• Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005; 10: 642–650
   PubMed Web of Science ®Google Scholar
• Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Journal of Clinical Oncology 2005; 23: 2606–2617
   PubMed Web of Science ®Google Scholar
• RED BOOK™. Drug References. Thomson Healthcare, 2007. Available at: http://www.micromedex.com/products/redbook [accessed September 2007]
   Google Scholar
• Department of Health & Human Services. Report to the President: prescription drug coverage, spending, utilization, and prices. Department of Health & Human Services, 2000. Available at: http://aspe.hhs.gov/health/reports/drugstudy/ [accessed September 2006]
   Google Scholar
• Hsiao WC, Braun P, Dunn D, et al. Resource-based relative values: an overview. Journal of the American Medical Association 1988; 260: 2347–2353
   PubMed Web of Science ®Google Scholar
• Federal Register. Medicare Program; Revisions to Payment Policies, etc.; Final Rule. Department of Health and Human Services, Centers for Medicare & Medicaid Services 2006; 71((231, part 2):)69623–70274
   Google Scholar
• Department of Health and Human Services: Office of the Inspector General. Use of Modifier 25. Available at: http://www.ouhsc.edu/bc/documents/oei-07-03-00470useofmod25_000.pdf [accessed November 2006]
   Google Scholar
• Barnor IF, Namovicz-Peat S. Highlights from AIS's database of health plans. . In: AIS's Directory of Health Plans: 2007 Atlantic Information Services, Inc., 2007
   Google Scholar
• Ries LAG, Melbert D, Krapcho M et al.SEER Cancer Statistics Review, 1975–2004. National Cancer Institute. 5-year limited duration prevalence. Bethesda, MD: NCI. Available at: http://seer.cancer.gov/csr/1975_2004/ (based on November 2006 SEER data submission, posted to the SEER website, 2007) [accessed November 2007]
   Google Scholar
• Amgen US Tandem Cancer Patient Audit, 1999–2001
   Google Scholar
• Amgen US Tandem Cancer Patient Audit, 2007.
   Google Scholar
• Centers for Medicare & Medicaid Services Medicare Part B Drug Average Sales Price: October 2007 ASP Pricing File (Q4). Available at: http://www.cms.hhs.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/October07ASPbyHCPCS_091807.zip [accessed September 2007]
   Google Scholar
• Rosberg JH, Ben-Hamadi R, Cremieux PY, et al. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis. Clinical Drug Investigation 2005; 25: 33–48
   PubMed Web of Science ®Google Scholar
• Taylor K, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 2005; 106: 992A–993A (abstract 3556).
   Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9: 696–707
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Comparative Effectiveness Review Number 3. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Available at: http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=4&DocID=35
   Google Scholar
• Berger A, Kallich J, Oster G. Use of darbepoetin alfa and epoetin alfa for cancer-related anemia in clinical practice. In: MASCC/ISOO 18th International Symposium; 22 June 2006; Toronto, Canada. Poster.
   Google Scholar
• Berger A, Edelsberg J, Kallich JD, et al. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-induced anemia. Clinical Therapeutics. 2008; 30: 206–218
   Google Scholar
• Song X, Long SR, Marder WD, et al. The impact of methodological approach on findings of average weekly dose and cost comparisons between epoetin alfa and darbepoetin alfa. Journal of Managed Care Pharmacy (in press)
   Google Scholar
• Reed SD, Radeva JI, Daniel DB, et al. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. PharmacoEconomics 2006; 24: 479–494
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clinical Therapeutics 2006; 28: 801–831
   PubMed Web of Science ®Google Scholar
• Kallich JD, Tchekmedyian NS, Damiano AM, et al. Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park, N.Y.) 2002; 16: 117–124
   Google Scholar
• Houts AC, Loh GA, Fortner BV, et al. Patient and caregiver time burden associated with anaemia treatment in different patient populations. Supportive Care in Cancer 2006; 14: 1195–1204
   PubMed Web of Science ®Google Scholar
• Meehan K, Tchekmedyian S, Ciesla G, et al. The burden of weekly epoetin alfa injections to patients and their caregivers. Proceedings of the American Society of Clinical Oncology 2003; 22: 543
   Google Scholar
• Cremieux P, Vekeman F, Lefebvre P. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application. Journal of Oncology Pharmacy Practice 2006; 12: 165–178
   PubMedGoogle Scholar
• Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Current Medical Research and Opinion 2004; 20: 381–395
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications. (CAG-0383N). 30 July 2007.
   Google Scholar